NASPCC

[NASPCC @NASPCC1]

New Aetna Policy for PSMA Screening for PLUVICTO Radioligand Therapy

https://t.co/cd9x3pukav

[NASPCC @NASPCC1]

Web-Based Peer Navigation for Men with Prostate Cancer and Their Family Caregivers: A Pilot Feasibility Study.

https://t.co/pAt91eqyzB

[NASPCC @NASPCC1]

Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.

https://t.co/iXROUZ5o4c

[NASPCC @NASPCC1]

Neurotoxicities of Novel Non-Steroidal Anti-Androgens for Prostate Cancer: A Systematic Review and Meta-Analysis - Beyond the Abstract

https://t.co/1eOX8TSQJq

[NASPCC @NASPCC1]

Variability in Testosterone Measurement Between Radioimmunoassay (RIA), Chemiluminescence Assay (CLIA) and Liquid Chromatography-Tandem Mass Spectrometry (MS) Among Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) - Beyond the Abstract

https://t.co/pA8VowfcDW

[NASPCC @NASPCC1]

Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.

https://t.co/dTZV3YzhEq

[NASPCC @NASPCC1]

Fusion heralds FDA tumor therapy clearance

https://t.co/p2nlvDUTKy

[NASPCC @NASPCC1]

Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719).

https://t.co/DW45EiCVpB

[NASPCC @NASPCC1]

Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes.

https://t.co/dZ8OhSH2Z1

[NASPCC @NASPCC1]

Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.

https://t.co/PonsnzJiGZ

[NASPCC @NASPCC1]

Two Specialists, Two Recommendations: Discordance between Urologists' & Radiation Oncologists' Prostate Cancer Treatment Recommendations.

https://t.co/bbU8eAffg7

[NASPCC @NASPCC1]

Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.

https://t.co/IolQigUvWn

[NASPCC @NASPCC1]

Transperineal vs Transrectal Prostate Biopsy: Is One Better?

https://t.co/o9fUqp92u8

[NASPCC @NASPCC1]

Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial

https://t.co/kRxLxCoWVA

[NASPCC @NASPCC1]

Variation and Disparity in the Use of Prostate Cancer Risk Stratification Tools in the United States.

https://t.co/77lNoxEW18

[NASPCC @NASPCC1]

PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study.

https://t.co/twG2fVYSKb

[NASPCC @NASPCC1]

EAU 2022: Metastatic Prostate Cancer: Possible Synergies Between Radioligand and Systemic Treatment in M1 Prostate Cancer? Future Perspectives

https://t.co/4LLetVnWG5

[NASPCC @NASPCC1]

EAU 2022: Recurrent Prostate Cancer: Salvage Treatment Options for the PSMA Avid Lesion - Radiotherapy

https://t.co/0U3PoiCKxv

[NASPCC @NASPCC1]

EAU 2022: Recurrent Prostate Cancer: Treatment Landscape of Hormone Sensitive Recurring M1 Prostate Cancer

https://t.co/GHktTPeVpx

[NASPCC @NASPCC1]

EAU 2022: Lifetime Risk of Prostate Cancer Death Among High-Risk Germline Mutation Carriers

https://t.co/5KvbbX7QV7